Citrix Systems, Inc.(NASDAQ:CTXS)went down 6.98% and closed at $62.94 on a traded volume of 9.07 million shares.The Company released first quarter results. Citrix reported profit of $59.7 million or 32 cents per share from $68.3 million or 36 cents a ...

Ironwood Pharmaceuticals, Inc (NASDAQ:IRWD) most recently priced a public offering of 10.5 million shares of Class A common stock at $13.00 a share.

Ironwood Pharmaceuticals has a 52 week low of $10.01 and a 52 week high of $19.67. The stock's 50-day moving average is currently $17.6.

NEW YORK, May 14, 2013 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week(R) 2013 in Orlando, Fla.

Ironwood Pharmaceuticals this week ran into one of the most common dilemmas for biotech companies. It needed to raise cash, but doing so caused shares to fall -- by around 11% in this case.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) ended -4.30% lower to $12.91 after ranging from $12.65 to $13.65 as has priced an underwritten public offering of 10,500,000 shares of its Class A common stock at $13.00 per share.

Looking back to 2 days ago, Ironwood Pharmaceuticals Inc. (NASD: IRWD) priced a 10,500,000 share secondary stock offering at $13.00 per share.

NEW YORK (AP) - A Cowen & Co. analyst downgraded shares of Ironwood Pharmaceuticals Inc. Monday, citing the company's growing expenses and disappointing early sales of its bowel drug Linzess.

Ironwood Pharmaceuticals Inc. (IRWD) has begun selling 10.5 million Class A shares, with the intention of using net proceeds to support the commercial launch of its Linzess drug to treat certain types of irritable bowel syndrome in adults.

Ironwood Pharmaceuticals, Inc. ( IRWD ) is -0.16 at $13.33, with 303,016 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2013.